Logo
x

Search

Subscribe Now

novartis

Astellas’ Padcev Plus Keytruda Receives the EC’s Approval to Treat Advanced Urothelial Cancer

Astellas’ Padcev Plus Keytruda Receives the EC’s Approval to Treat Advanced Urothelial Cancer

  • August 28, 2024
Novartis Reports Topline Data from P-III (V-MONO) Trial of Leqvio (Inclisiran) in Patients at Atherosclerotic Cardiovascular Disease (ASCVD) Risk

Novartis Reports Topline Data from P-III (V-MONO) Trial of Leqvio (Inclisiran) in Patients at Atherosclerotic Cardiovascular Disea...

  • August 28, 2024
Novartis Highlights the P-III (REMIX) Trial Data of Remibrutinib to Treat Chronic Spontaneous Urticaria at EAACI 2024

Novartis Highlights the P-III (REMIX) Trial Data of Remibrutinib to Treat Chronic Spontaneous Urticaria at EAACI 2024

  • May 31, 2024
Novartis Highlights Results from the P-III (ALIGN) Study of Atrasentan for the Treatment of IgA Nephropathy (IgAN) at ERA 2024

Novartis Highlights Results from the P-III (ALIGN) Study of Atrasentan for the Treatment of IgA Nephropathy (IgAN) at ERA 2024

  • May 27, 2024
Novartis to Acquire Mariana Oncology, Expanding its Radioligand Therapy Pipeline

Novartis to Acquire Mariana Oncology, Expanding its Radioligand Therapy Pipeline

  • May 3, 2024
Novartis Reports Data from the P-III Study of Fabhalta (iptacopan) for the Treatment of IgA Nephropathy (IgAN)

Novartis Reports Data from the P-III Study of Fabhalta (iptacopan) for the Treatment of IgA Nephropathy (IgAN)

  • April 16, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.